XanthoPharm Welcomes Dr Luis Gandia
to its Scientific Advisory Board (SAB)
Weymouth, MA. April 28, 2021
XanthoPharm, a therapeutics company dedicated to developing novel therapeutics for the treatment of arrhythmias welcomes Drs Luis Gandia to its SAB. Dr Gandia will be a significant resource for XanthoPharm to help guide our preclinical work, provide scientific review and strategic advice about the company’s development strategy.
“We are honored to officially welcome Dr Gandia as a member of our SAB,” said Bob Jenkins, CEO of XanthoPharm. “Dr. Gandia´s considerable experience as an advisor within the pharmaceutical industry and, more specifically, in the screening and development of new drug candidates will help us guide our research strategy in the future. Additionally, his track record in basic research will assist us in further developing our own basic research pathway and communicating our results to the wider community to evaluate the therapeutic applicability of xanthohumol in further indications.”
The SAB will be involved in strategic discussions related to our research, both clinical and pre-clinical, as well as our developmental strategy and pipeline.
About Luis Gandia
Luis Gandia is Full Professor of Pharmacology and Chairman of the Department of Pharmacology and Therapeutics in the Faculty of Medicine of the Autonomous University of Madrid. He obtained his PhD in Neuroscience from the University of Alicante in 1990. He dedicated his postdoctoral work at the University of Pennsylvania in specializing in electrophysiological and microscopy techniques. During his career, Luis has a wide-ranging experience in all phases of pharmacological development, with a particular emphasis on the preclinical development of new drugs.
About XanthoPharm
XanthoPharm is a therapeutics company dedicated to the development of xanthohumol for the treatment of arrhythmias in general and atrial fibrillation in particular. Atrial fibrillation (Afib) is the most common of all arrhythmias and its pharmaceutical management problematic. Our goal is to bring a therapeutic to Afib patients that is both efficacious and safe